Their findings also showed that treatment with an anti-CD25 antibody, which is widely used to deplete Foxp3+CD25+ Tregs in mice, failed to reduce tumor growth, likely due to the simultaneous depletion of tumor-specific CD8+ T cells [47]. This evidence concerns the gene CD8A and neoplasm.